Beam Therapeutics Stock Buy Hold or Sell Recommendation
| BEAM Stock | USD 24.23 0.83 3.31% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Beam Therapeutics is 'Cautious Hold'. The recommendation algorithm takes into account all of Beam Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Beam Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide. Note, we conduct extensive research on individual companies such as Beam and provide practical buy, sell, or hold advice based on investors' constraints. Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Beam |
Execute Beam Therapeutics Buy or Sell Advice
The Beam recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Beam Therapeutics. Macroaxis does not own or have any residual interests in Beam Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Beam Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Beam Therapeutics Trading Alerts and Improvement Suggestions
| Beam Therapeutics generated a negative expected return over the last 90 days | |
| Beam Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 63.52 M. Net Loss for the year was (376.74 M) with loss before overhead, payroll, taxes, and interest of (304.04 M). | |
| Beam Therapeutics currently holds about 1.09 B in cash with (347.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.9. | |
| Beam Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 79.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thefly.com: Beam Therapeutics price target raised by 8 at Citi, heres why BEAM |
Beam Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Beam analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Beam analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Beam Therapeutics Returns Distribution Density
The distribution of Beam Therapeutics' historical returns is an attempt to chart the uncertainty of Beam Therapeutics' future price movements. The chart of the probability distribution of Beam Therapeutics daily returns describes the distribution of returns around its average expected value. We use Beam Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Beam Therapeutics returns is essential to provide solid investment advice for Beam Therapeutics.
| Mean Return | -0.04 | Value At Risk | -8.18 | Potential Upside | 8.04 | Standard Deviation | 4.59 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Beam Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Beam Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Beam Therapeutics, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Beam Therapeutics back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-12-31 | 1.8 M | Temasek Holdings Ltd. | 2024-12-31 | 1.8 M | Geode Capital Management, Llc | 2024-12-31 | 1.8 M | Kynam Capital Management, Lp | 2024-12-31 | 1.8 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 1.8 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.5 M | Redmile Group, Llc | 2024-12-31 | 1.5 M | Bellevue Group Ag | 2024-12-31 | 1.5 M | Casdin Capital, Llc | 2024-12-31 | 1.2 M | Farallon Capital Management, L.l.c. | 2024-12-31 | 8.2 M | Blackrock Inc | 2024-12-31 | 7.7 M |
Beam Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 126.5M | 395.7M | (327.2M) | 199.1M | (154.5M) | (146.8M) | |
| Free Cash Flow | (112.1M) | (113.1M) | (26.4M) | (182.9M) | (356.2M) | (338.4M) | |
| Depreciation | 4.7M | 7.5M | 14.1M | 20.0M | 31.6M | 33.2M | |
| Other Non Cash Items | 9.9M | 158.9M | (38.5M) | (18.9M) | (2.1M) | (2.0M) | |
| Capital Expenditures | 16.4M | 46.8M | 49.0M | 33.7M | 8.9M | 8.5M | |
| Net Income | (194.6M) | (370.6M) | (289.1M) | (132.5M) | (376.7M) | (357.9M) | |
| End Period Cash Flow | 177.0M | 572.7M | 245.5M | 444.6M | 290.1M | 265.4M | |
| Investments | (83.0M) | (248.0M) | (461.3M) | 87.2M | 185.0M | 194.3M | |
| Change To Netincome | 13.5M | 88.8M | 185.7M | 16.9M | 19.5M | 18.5M |
Beam Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Beam Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Beam Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Beam stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.06 | |
β | Beta against Dow Jones | 1.08 | |
σ | Overall volatility | 4.51 | |
Ir | Information ratio | 0.01 |
Beam Therapeutics Volatility Alert
Beam Therapeutics exhibits very low volatility with skewness of 0.24 and kurtosis of 0.4. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Beam Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Beam Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Beam Therapeutics Fundamentals Vs Peers
Comparing Beam Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Beam Therapeutics' direct or indirect competition across all of the common fundamentals between Beam Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Beam Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Beam Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Beam Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Beam Therapeutics to competition |
| Fundamentals | Beam Therapeutics | Peer Average |
| Return On Equity | -0.44 | -0.31 |
| Return On Asset | -0.2 | -0.14 |
| Operating Margin | (3.33) % | (5.51) % |
| Current Valuation | 1.81 B | 16.62 B |
| Shares Outstanding | 99.84 M | 571.82 M |
| Shares Owned By Insiders | 1.21 % | 10.09 % |
| Shares Owned By Institutions | 79.06 % | 39.21 % |
| Number Of Shares Shorted | 9.24 M | 4.71 M |
| Price To Earning | 37.48 X | 28.72 X |
| Price To Book | 3.41 X | 9.51 X |
| Price To Sales | 38.09 X | 11.42 X |
| Revenue | 63.52 M | 9.43 B |
| Gross Profit | (304.04 M) | 27.38 B |
| EBITDA | (415.57 M) | 3.9 B |
| Net Income | (376.74 M) | 570.98 M |
| Cash And Equivalents | 1.09 B | 2.7 B |
| Cash Per Share | 15.90 X | 5.01 X |
| Total Debt | 161.43 M | 5.32 B |
| Debt To Equity | 0.25 % | 48.70 % |
| Current Ratio | 4.64 X | 2.16 X |
| Book Value Per Share | 9.05 X | 1.93 K |
| Cash Flow From Operations | (347.25 M) | 971.22 M |
| Short Ratio | 7.51 X | 4.00 X |
| Earnings Per Share | (4.58) X | 3.12 X |
| Price To Earnings To Growth | (2.30) X | 4.89 X |
| Target Price | 49.07 | |
| Number Of Employees | 483 | 18.84 K |
| Beta | 1.91 | -0.15 |
| Market Capitalization | 2.42 B | 19.03 B |
| Total Asset | 1.1 B | 29.47 B |
| Retained Earnings | (1.57 B) | 9.33 B |
| Working Capital | 696.08 M | 1.48 B |
| Current Asset | 2.89 B | 9.34 B |
Note: Disposition of 6287 shares by Bethany Cavanagh of Beam Therapeutics at 35.0 subject to Rule 16b-3 [view details]
Beam Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Beam . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Beam Therapeutics Buy or Sell Advice
When is the right time to buy or sell Beam Therapeutics? Buying financial instruments such as Beam Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Beam Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corporate ETFs Thematic Idea Now
Corporate ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Corporate ETFs theme has 222 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corporate ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Beam Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.58) | Revenue Per Share | Quarterly Revenue Growth (0.91) | Return On Assets | Return On Equity |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.